Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...

杜氏肌营养不良症是一种罕见疾病，在美国和欧洲影响约41,000人，治疗选择有限。Entrada的EEV治疗平台旨在通过将治疗药物递送到细胞内，接触先前无法到达的细胞内靶点，从而满足这一未满足的医疗需求。

Entr'acte Theatrix' first production of 2025 will be Avenue Q, the Tony Award-winning musical. The production will run in the Bhetty Waldron Theatre at Actor's Rep in West Palm Beach. Learn more and ...

The Course focuses on innovation and entrepreneurship utilizing experiential learning and venturing projects. It will deal with ideation methods and tools, technology commercialization, business ...

(TRDA), a clinical-stage biopharmaceutical company, on Monday provided an update on its upcoming Phase 1/2 clinical trial for ENTR-601-44, a treatment for Duchenne muscular dystrophy or DMD in ...

This course is designed for students who are interested in entrepreneurship. The focus is on entrepreneurship as generic activity. It explores the opportunities and challenges face by individuals who ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Entrada Therapeutics plans to initiate ELEVATE-44-201 trial for ENTR-601-44 in Duchenne muscular dystrophy by Q2 2025. Entrada Therapeutics, Inc. announced that it has received regulatory ...

Entrada Therapeutics has secured authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to ...